$1.19
1.71% day before yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US5288723027
Symbol
LXRX

Lexicon Pharmaceuticals, Inc. Stock price

$1.19
-0.01 0.83% 1M
+0.49 69.47% 6M
+0.45 61.14% YTD
-0.64 34.97% 1Y
-1.68 58.54% 3Y
-0.54 31.21% 5Y
-10.49 89.81% 10Y
-30.38 96.23% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.02 1.71%
ISIN
US5288723027
Symbol
LXRX
Industry

Key metrics

Basic
Market capitalization
$432.4m
Enterprise Value
$349.5m
Net debt
positive
Cash
$139.0m
Shares outstanding
363.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.4 | 30.7
EV/Sales
6.0 | 24.8
EV/FCF
negative
P/B
3.3
Financial Health
Equity Ratio
48.9%
Return on Equity
-137.3%
ROCE
-62.1%
ROIC
-
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$58.4m | $14.1m
EBITDA
$-117.8m | $-181.5m
EBIT
$-118.4m | $-146.0m
Net Income
$-120.6m | $-144.3m
Free Cash Flow
$-102.7m
Growth (TTM | estimate)
Revenue
1,487.8% | -54.6%
EBITDA
40.1% | 7.7%
EBIT
39.9% | 26.0%
Net Income
40.3% | 28.0%
Free Cash Flow
47.7%
Margin (TTM | estimate)
Gross
99.2%
EBITDA
-201.6% | -1,286.3%
EBIT
-202.6%
Net
-206.4% | -1,023.1%
Free Cash Flow
-175.7%
More
EPS
$-0.3
FCF per Share
$-0.3
Short interest
20.8%
Employees
103
Rev per Employee
$300.0k
Show more

Is Lexicon Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Lexicon Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

Buy
73%
Hold
27%

Financial data from Lexicon Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
58 58
1,488% 1,488%
100%
- Direct Costs 0.48 0.48
78% 78%
1%
58 58
1,599% 1,599%
99%
- Selling and Administrative Expenses 93 93
32% 32%
159%
- Research and Development Expense 84 84
30% 30%
143%
-118 -118
40% 40%
-202%
- Depreciation and Amortization 0.60 0.60
11% 11%
1%
EBIT (Operating Income) EBIT -118 -118
40% 40%
-203%
Net Profit -121 -121
40% 40%
-206%

In millions USD.

Don't miss a Thing! We will send you all news about Lexicon Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexicon Pharmaceuticals, Inc. Stock News

Positive
The Motley Fool
17 days ago
Lexicon (LXRX) Q2 Revenue Soars 1,706%
Neutral
Seeking Alpha
17 days ago
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Craig B. Granowitz - Senior VP & Chief Medical Officer Lisa M.
Neutral
GlobeNewsWire
18 days ago
Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference c...
More Lexicon Pharmaceuticals, Inc. News

Company Profile

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Head office United States
CEO Michael Exton
Employees 103
Founded 1995
Website www.lexpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today